Continuous CSF drainage in AD: Results of a double-blind, randomized, placebo-controlled study
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer disease (AD) has been associated with abnormal cerebral clearance of macromolecules, such as amyloid and microtubule-associated-protein tau (MAP-τ). We hypothesized that improving clearance of macromolecules from the CNS might slow the progression of dementia. Objective: This prospective, randomized, double-blinded, placebo-controlled trial evaluated the safety and effectiveness of a surgically implanted shunt in subjects with probable AD. Methods: A total of 215 subjects with probable AD by National Institute of Neurological Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association criteria received either a low-flow ventriculoperitoneal shunt or a sham (occluded) shunt for 9 months. Longitudinal CSF sampling was performed in both active and control subjects. Primary outcome measures were the Mattis Dementia Rating Scale and the Global Deterioration Scale. CSF Aβ(1-42) and MAP-τ also were assayed. Results: After a planned interim analysis, the study was halted for futility. Using the intent-to-treat population, no between-group differences were observed in the primary outcome measures. The surgical procedure and device were associated with 12 CNS infections, some temporally associated with CSF sampling. All were treated successfully. Conclusions: We found no benefit to low-flow CSF shunting in subjects with mild to severe Alzheimer disease. CSF infections, while treatable, occurred more frequently than expected, in some cases likely related to CSF sampling. GLOSSARY: Aβ = amyloid beta-peptides; AD = Alzheimer disease; ADCS-ADL = AD Cooperative Study Activities of Daily Living; BBB = blood–brain barrier; CP = choroid plexus; FDA = Food and Drug Administration; GDS = Global Deterioration Scale; GEE = Generalized Estimating Equations; IA = interim analysis; ISF = interstitial fluid; ITT = intent-to-treat; LRP-1 = lipoprotein receptor-related protein-1; MAP-τ = microtubule-associated-protein tau; MDRS = Mattis Dementia Rating Scale; MMSE = Mini-Mental State Examination; NAART = North American Adult Reading Test; NINCDS-ADRDA = National Institutes of Neurological and Communicative Diseases and Stroke–Alzheimer’s Disease and Related Disorders Association; NPH = normal-pressure hydrocephalus; PHF = perihippocampal fissures; RAGE = receptor for advanced glycation end-products; SADAS-Cog = Standardized AD Assessment Scale–Cognitive; SAE = serious adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 10×
“Table 3 contains the results of the CSF analyses of MAP- and A (1-42) in the two treatment groups.”
BackgroundMethodResultInfluentialRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Aging renders the brain vulnerable to amyloid β-protein neurotoxicity
Guela, C., Wu, C.-K., Saroff, D., Lorenzo, A., Yuan, M., & Yankner, B. A. (1998) · Nature Medicine · doi:10.1038/nm0798-827 · Cited by 520
RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
Self-citationKanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340
Cited by
Use of placebo controls in the evaluation of surgery: systematic review
Wartolowska, K., Judge, A., Hopewell, S., Collins, G. S., Dean, B. J. F., Rombach, I., Brindley, D., Savulescu, J., Beard, D. J., & Carr, A. J. (2014) · BMJ · doi:10.1136/bmj.g3253 · Cited by 282
Zhang, Z., Song, M., Liu, X., Su Kang, S., Duong, D. M., Seyfried, N. T., Cao, X., Cheng, L., Sun, Y. E., Ping Yu, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9762 · Cited by 277
Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET
de Leon, M. J., Li, Y., Okamura, N., Tsui, W. H., Saint-Louis, L. A., Glodzik, L., Osorio, R. S., Fortea, J., Butler, T., Pirraglia, E., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.187211 · Cited by 246
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
Seppälä, T. T., Nerg, O., Koivisto, A. M., Rummukainen, J., Puli, L., Zetterberg, H., Pyykkö, O. T., Helisalmi, S., Alafuzoff, I., Hiltunen, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bd0 · Cited by 236
Deconstructing normal pressure hydrocephalus: ventriculomegaly as early sign of neurodegeneration
Espay, A. J., Da Prat, G. A., Dwivedi, A. K., Rodriguez‐Porcel, F., Vaughan, J. E., Rosso, M., Devoto, J. L., Duker, A. P., Masellis, M., Smith, C. D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25046 · Cited by 208
Metadata
- Authors
- Silverberg, G. D., Mayo, M., Saul, T., Fellmann, J., Carvalho, J., & McGuire, D.
- Venue
- Neurology
- Published
- 2008-07-15
- Volume
- 71
- Issue
- 3
- Pages
- 202-209
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2088264839
- Cited by
- 87
- References
- 9
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous CSF drainage in AD: Results of a double-blind, randomized, placebo-controlled study. https://app.cochat.ai/papers/10.1212/01.wnl.0000316197.04157.6f
- The paper
- Silverberg, G. D., Mayo, M., Saul, T., Fellmann, J., Carvalho, J., & McGuire, D. (2008). Continuous CSF drainage in AD: Results of a double-blind, randomized, placebo-controlled study. Neurology. https://doi.org/10.1212/01.wnl.0000316197.04157.6f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.